Sandoz cuts sales outlook, raises profit margin forecast after biosimilar supply constraints

Sandoz cuts sales outlook, raises profit margin forecast after biosimilar supply constraints
Sandoz outlook shifts

Short-term supply constraints in biosimilars are weighing on Sandoz's third-quarter performance and prompting the Swiss drugmaker to revise its full-year targets. The company now expects slower sales growth in 2026 while forecasting a stronger core earnings margin than previously indicated.

Highlights

  • Sandoz lowers 2024 net sales growth guidance to 5%-6% but raises 2026 core EBITDA margin target to 23%-23.5%.
  • Third-quarter net sales of $2.94 billion and biosimilars unit sales of $998 million both fall short of analyst expectations.
  • Challenging market conditions in Germany and no material 2024 sales expected from generic semaglutide offset North America-led biosimilar growth.

Updated guidance and quarterly performance

As reported by Reuters, Sandoz says it now expects net sales to grow by 5% to 6% at constant exchange rates, down from its previous expectation for mid-to-high-single-digit growth. At the same time, it lifts its core EBITDA margin forecast to 23% to 23.5% in 2026, compared with earlier guidance for an increase of around 100 basis points from the 21.7% recorded in 2025.

Third-quarter net sales come in at $2.94 billion, below the $3.01 billion expected by analysts in a Vara Research-compiled consensus. The biosimilars unit also slightly misses forecasts, posting net sales of $998 million, up 17% at constant exchange rates from the same period last year but below the $1.02 billion analysts had expected.

Market conditions and medium-term growth plans

After expanding its biosimilars business in Europe, Sandoz says market conditions in Germany prove more challenging than anticipated, while North America leads sales in the quarter. The company also says no material contribution from the launch of generic semaglutide is expected this year, despite approvals in Brazil and Canada in the diabetes and obesity market.

At its September capital markets day, Sandoz outlines medium-term expansion plans that aim to more than double annual net sales by 2035 and increase its biosimilars portfolio to 100 drugs by 2040 from 13. Separately, the company filed an anti-dumping complaint with the European Commission in March over imports of Chinese amoxicillin active pharmaceutical ingredients, accusing manufacturers of distorting the market.

Our earlier article on Mycron Steel Bhd’s anti-dumping dispute explained how the company withdrew its judicial review challenging the government’s move to abolish anti-dumping duties on certain imported steel products. We noted that the withdrawal followed what Mycron described as constructive discussions and shifted attention to how the policy change could affect price competition and supply dynamics in the local market.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.